Avantor, Inc. (NYSE:AVTR – Get Free Report) has earned an average rating of “Moderate Buy” from the thirteen brokerages that are covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $27.69.
Several equities analysts recently weighed in on AVTR shares. Barclays reduced their price target on shares of Avantor from $28.00 to $25.00 and set an “overweight” rating for the company in a research report on Friday, October 25th. Robert W. Baird dropped their price objective on Avantor from $27.00 to $26.00 and set an “outperform” rating on the stock in a research note on Monday, October 28th. UBS Group lowered their target price on Avantor from $30.00 to $29.00 and set a “buy” rating on the stock in a research note on Tuesday, October 8th. Wells Fargo & Company cut their price target on Avantor from $30.00 to $28.00 and set an “overweight” rating for the company in a research note on Monday, October 28th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $34.00 target price on shares of Avantor in a research report on Thursday, September 26th.
Read Our Latest Research Report on Avantor
Institutional Inflows and Outflows
Avantor Stock Performance
Shares of AVTR opened at $21.41 on Thursday. The stock has a 50 day moving average of $21.80 and a 200 day moving average of $23.36. The company has a market capitalization of $14.57 billion, a price-to-earnings ratio of 46.54, a PEG ratio of 2.75 and a beta of 1.29. Avantor has a 12 month low of $19.59 and a 12 month high of $28.00. The company has a current ratio of 1.54, a quick ratio of 1.06 and a debt-to-equity ratio of 0.84.
About Avantor
Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.
See Also
- Five stocks we like better than Avantor
- What is Put Option Volume?
- Buffett Takes the Bait; Berkshire Buys More Oxy in December
- Stock Splits, Do They Really Impact Investors?
- Top 3 ETFs to Hedge Against Inflation in 2025
- Election Stocks: How Elections Affect the Stock Market
- These 3 Chip Stock Kings Are Still Buys for 2025
Receive News & Ratings for Avantor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avantor and related companies with MarketBeat.com's FREE daily email newsletter.